Patient Selection and Assessment Criteria for patient eligibility, medical history and contraindications According to the package insert: Wegovy (semaglutide) injection 2.4 mg is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management: YES: adults with an initial body mass index (BMI) of 30 kg/m2 (obesity) or 27 kg/m2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia) pediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater standardized for age and sex (obesity) NO: Patients with a personal or family history of MTC Patients with MEN 2 Patients with a prior serious hypersensitivity reaction to semaglutide or to any of the excipients in semaglutide WARNING & PRECAUTIONS: Risk of the following: Thyroid C-Cell Tumors Acute Pancreatitis Acute Gallbladder Disease Hypoglycemia Acute Kidney Injury Hypersensitivity Reactions Diabetic Retinopathy Complications in Patients with Type 2 Diabetes Heart Rate Increase Suicidal Behavior and Ideation ADDITIONAL Patients should be warned about the following: History of type 1 diabetes or diabetic ketoacidosis, as semaglutide is not indicated for these conditions
This significant weight loss can have a positive impact on overall health and reduce the risk of obesity-related comorbidities such as cardiovascular disease and type 2 diabetes
Effectiveness : Patients lose up to 15% of their body weight with Semaglutide, compared to around 8% with Liraglutide
Side Effects: Whats Common and How to Manage It Some people tolerate tirzepatide and semaglutide well, while others struggle with the side effects
Activating our GLP-1 receptors sends a signal to increase insulin secretion and decrease glucagon secretion, which helps lower blood sugar levels
For patients using Ozempic for weight loss, the risk is even more pronounced
